Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2020

01-04-2020 | Lymphadenopathy | Original Article

Clinicopathological Profile of Castleman’s Disease in Indian Population: Experience From a Tertiary Care Center

Authors: Ashok Singh, Suvendu Purkait, Saumyaranjan Mallick, Prashant Ramteke, Chandan Krushna Das, Ajay Gogia, Maher Chand Sharma, Lalit Kumar

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2020

Login to get access

Abstract

Castleman’s disease (CD), also known as angiofollicular lymph node hyperplasia, a rare, non-malignant chronic lymphoproliferative disease characterized by, uni or multicentric lymphadenopathy. There is limited information about the clinicopathological variations and associations of this entity. A total of 50 cases of CD were retrieved from the archives, between the years 2005–2017. The cases were divided into pediatric (0–18 years), young adult (age ≤ 40 years) and older adult groups (age > 40 years respectively). Detailed clinicopathological correlation was done. The age range was 6–74 years. There was a male predominance (M: F—1.6:1). The majority (72%; 36/50) of the patients were adults; 46% young adult and 28% older adult, while only 28% (14/50) were of pediatric. Majority (78%) showed features of unicentric Castleman disease (UCD) while rest 22% presented with multi centric Castleman disease (MCD). Systemic symptoms were more frequent in MCD as compared to UCD cases (p = 0.06). The majority of the cases (40/50; 80%) were of the hyaline vascular type. Two of the cases showed mixed histological feature. Out of 50 patients 29 patient’s treatment details are available. Majority unicentric cases were cases surgically excised 14/17 (82.3%). Three patients 3/17 (17.6%) were treated with chemotherapy. In multicentric Castleman’s disease group, six of the 12 cases with MCD were managed by chemotherapy. One patient died of progressive disease. Castleman disease has varied clinical presentation and is often associated with other diseases. A high degree of suspicion and careful histological examination is required in order not to miss this entity.
Literature
1.
go back to reference Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot N Engl J Med 251:396–400CrossRef Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot N Engl J Med 251:396–400CrossRef
2.
go back to reference Castleman B, Iverson L, Menendez V (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822/30.CrossRef Castleman B, Iverson L, Menendez V (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822/30.CrossRef
3.
go back to reference Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683CrossRef Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683CrossRef
4.
go back to reference Frizzera G, Peterson BA, Bayrd ED et al (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J ClinOncol 3:1202–1216CrossRef Frizzera G, Peterson BA, Bayrd ED et al (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J ClinOncol 3:1202–1216CrossRef
5.
go back to reference Bowne WB, Lewis JJ, Filippa DA et al (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717CrossRef Bowne WB, Lewis JJ, Filippa DA et al (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717CrossRef
6.
go back to reference Peterson BA, Frizzera G (1993) Multicentric Castleman’sdisease. Semin Oncol 20:636–647PubMed Peterson BA, Frizzera G (1993) Multicentric Castleman’sdisease. Semin Oncol 20:636–647PubMed
7.
go back to reference Talat N, Schulte KM (2011) Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 16:1316–1324CrossRef Talat N, Schulte KM (2011) Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 16:1316–1324CrossRef
8.
go back to reference Kawabata H, Kadowaki N, Nishikori M et al (2013) Clinical features and treatment of multicentriccastleman'sdisease: a retrospective study of 21 Japanese patients at a single institute. J ClinExpHematop 53:69–77 Kawabata H, Kadowaki N, Nishikori M et al (2013) Clinical features and treatment of multicentriccastleman'sdisease: a retrospective study of 21 Japanese patients at a single institute. J ClinExpHematop 53:69–77
9.
go back to reference Shin DY, Jeon YK, Hong YS et al (2011) Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 52:1517–1522CrossRef Shin DY, Jeon YK, Hong YS et al (2011) Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 52:1517–1522CrossRef
10.
go back to reference Kojima M, Nakamura S, Miyawaki S, Ohno Y, Sakela N, Majawa N (2005) Progressive transformation of germinal center presenting with histological features of hyaline-vascular type of Castleman’s disease. APMIS 113:288–295CrossRef Kojima M, Nakamura S, Miyawaki S, Ohno Y, Sakela N, Majawa N (2005) Progressive transformation of germinal center presenting with histological features of hyaline-vascular type of Castleman’s disease. APMIS 113:288–295CrossRef
11.
go back to reference Ghosh A, Pradhan SV, Talwar OP (2010) Castleman's disease—hyaline vascular type—clinical, cytological and histological features with review of literature. Indian J PatholMicrobiol 53:244–247 Ghosh A, Pradhan SV, Talwar OP (2010) Castleman's disease—hyaline vascular type—clinical, cytological and histological features with review of literature. Indian J PatholMicrobiol 53:244–247
12.
go back to reference Waterston A, Bower M (2004) Fifty years of multicentric Castleman's disease. Acta Oncol 43:698–704CrossRef Waterston A, Bower M (2004) Fifty years of multicentric Castleman's disease. Acta Oncol 43:698–704CrossRef
13.
go back to reference Ye B, Gao SG, Li W et al (2010) A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients. Med Oncol 27:1171–1178CrossRef Ye B, Gao SG, Li W et al (2010) A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients. Med Oncol 27:1171–1178CrossRef
14.
go back to reference Dong Y, Wang M, Nong L et al (1983) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: pathological findings in 15 patients. Am J SurgPathol 7:211–231 Dong Y, Wang M, Nong L et al (1983) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: pathological findings in 15 patients. Am J SurgPathol 7:211–231
15.
go back to reference Luo JM, Li S, Huang H et al (2015) Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital. BMC Pulm Med 15:34CrossRef Luo JM, Li S, Huang H et al (2015) Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital. BMC Pulm Med 15:34CrossRef
16.
go back to reference Oksenhendler E, Carcelain G, Aoki Y et al (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96:2069–2073CrossRef Oksenhendler E, Carcelain G, Aoki Y et al (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96:2069–2073CrossRef
17.
go back to reference Kojima M, Nakamura N, Tsukamoto N et al (2008) Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J SurgPathol 16:391–398 Kojima M, Nakamura N, Tsukamoto N et al (2008) Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J SurgPathol 16:391–398
18.
go back to reference Soumerai JD, Sohani AR, Abramson JS (2014) Diagnosis and management of Castleman disease. Cancer Control 21:266–278CrossRef Soumerai JD, Sohani AR, Abramson JS (2014) Diagnosis and management of Castleman disease. Cancer Control 21:266–278CrossRef
19.
go back to reference Zhang J, Li C, Lv L et al (2015) Clinical and experimental study of Castleman disease in children. Pediatr Blood Cancer 62:109–114CrossRef Zhang J, Li C, Lv L et al (2015) Clinical and experimental study of Castleman disease in children. Pediatr Blood Cancer 62:109–114CrossRef
20.
go back to reference Taylor KL, Kaschula ROC (1995) Castleman's disease in children: the experience of a children's hospital in Africa. Pediat Pathol Lab Med 15:857–868CrossRef Taylor KL, Kaschula ROC (1995) Castleman's disease in children: the experience of a children's hospital in Africa. Pediat Pathol Lab Med 15:857–868CrossRef
21.
go back to reference Herrada J, Cabanillas F, Rice L et al (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657–662CrossRef Herrada J, Cabanillas F, Rice L et al (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657–662CrossRef
22.
go back to reference deVries IA, van Acht MM, Demeyere T et al (2010) Neoadjuvant radiotherapy of primary irresectable unicentric Castleman’s disease: a case report and review of the literature. RadiatOncol 5:7CrossRef deVries IA, van Acht MM, Demeyere T et al (2010) Neoadjuvant radiotherapy of primary irresectable unicentric Castleman’s disease: a case report and review of the literature. RadiatOncol 5:7CrossRef
23.
go back to reference Loi S, Goldstein D, Clezy K et al (2004) Castleman’s disease and HIV infection in Australia. HIV Med 5:157–162CrossRef Loi S, Goldstein D, Clezy K et al (2004) Castleman’s disease and HIV infection in Australia. HIV Med 5:157–162CrossRef
24.
go back to reference Seo HY, Kim EB, Kim JW et al (2009) Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat 41:104–107CrossRef Seo HY, Kim EB, Kim JW et al (2009) Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat 41:104–107CrossRef
25.
go back to reference Lee JH, Kwon KA, Lee S et al (2010) Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res 34:e42–e45CrossRef Lee JH, Kwon KA, Lee S et al (2010) Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res 34:e42–e45CrossRef
Metadata
Title
Clinicopathological Profile of Castleman’s Disease in Indian Population: Experience From a Tertiary Care Center
Authors
Ashok Singh
Suvendu Purkait
Saumyaranjan Mallick
Prashant Ramteke
Chandan Krushna Das
Ajay Gogia
Maher Chand Sharma
Lalit Kumar
Publication date
01-04-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01191-w

Other articles of this Issue 2/2020

Indian Journal of Hematology and Blood Transfusion 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine